AKT1 and myocardial ischemia: Off note, 1-(3,6-Dibromo-carbazol-9-yl)-3-phenylamino-propan-2-ol, known for its ability to dimerize and aggregate visfatin, has been reported to decrease the infarction area in diabetic hearts throughout cardiac ischemia and reperfusion damage recently, together with molecular signaling modification for p-AKT, phosphorylated eNOS and SIRT1 [163]. Straightforwardly, more in-depth investigations are vital to examine the latent efficacy of visfatin in diabetic myocardial I/R injury.